Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $28.39 Analyst target: $47.88 Upside: 68.65%
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is headquartered in Waltham, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.